Medigen Biotechnology Cash Flow Quality Index

Latest as of March 2025: -0.28x

Medigen Biotechnology cash flow quality index. Medigen Biotechnology (3176) has a Cash Flow Quality Index of -0.28x as of March 2025. Operating cash flow of NT$-28.96 Million is below net income of NT$102.45 Million, suggesting accrual-heavy earnings not yet converted to cash. See Medigen Biotechnology (3176) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

-0.28x

Operating CF / Net Income

Operating Cash Flow

NT$-28.96 Million

TWD

Net Income

NT$102.45 Million

TWD

Data as of

Mar 2025

Most recent filing

Medigen Biotechnology Cash Flow Quality Index by Year (None–None)

Medigen Biotechnology cash flow quality index by year from None to None. Year-by-year earnings quality comparison for Medigen Biotechnology. For the full cash flow conversion analysis, see 3176 cash generation efficiency.

Year	Quality Index	Operating CF (TWD)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.